American Journal of Medical and Biological Research
ISSN (Print): 2328-4080 ISSN (Online): 2328-4099 Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
American Journal of Medical and Biological Research. 2019, 7(1), 12-19
DOI: 10.12691/ajmbr-7-1-3
Open AccessArticle

Immunoinformatic Approach for Designing Novel Universal Human Peptide Based Vaccine of Glycoprotein Receptor (M protein) against Rift Valley Fever Virus

Neama Esmat Mahmoud1, , Marwa Mohamed Osman2, Safa Ibrahim Gebril3, Romaisaa Mubarak Babiker3, Ruaa Mohamed Almardi3, Zainab Abd Elgafour Osman3, Sajda Mergany Silman3, Manasik gumah Adam3, Alsmawal Awad Elimam1, Zohal AbdalAzeem Bala1, Tarig Abdalleh Mohammed1 and Ayat Adil Mohammed1

1Faculty of medical laboratories sciences, Alneelain University- Khartoum, Sudan

2Department of Biotechnology, Africa city of Technology- Khartoum, Sudan

3Faculty of pharmacy, Khartoum University- Khartoum, Sudan

Pub. Date: September 19, 2019

Cite this paper:
Neama Esmat Mahmoud, Marwa Mohamed Osman, Safa Ibrahim Gebril, Romaisaa Mubarak Babiker, Ruaa Mohamed Almardi, Zainab Abd Elgafour Osman, Sajda Mergany Silman, Manasik gumah Adam, Alsmawal Awad Elimam, Zohal AbdalAzeem Bala, Tarig Abdalleh Mohammed and Ayat Adil Mohammed. Immunoinformatic Approach for Designing Novel Universal Human Peptide Based Vaccine of Glycoprotein Receptor (M protein) against Rift Valley Fever Virus. American Journal of Medical and Biological Research. 2019; 7(1):12-19. doi: 10.12691/ajmbr-7-1-3


Rift Valley fever virus (RVFV) is a single strand, negative sense, an envelope spherical particle, of size 80 - 120 nm, segmented RNA virus that belongs to Genus: Phlebovirus of Bunyaviridae family. The clinical manifestations of the disease among animals are abortion and death of newborns. While in humans, although the disease is mild or asymptomatic, there are several reports of high fatality rates. The M segment of RVF virus Genome which encodes the envelope glycoprotein has been used to design a vaccine for immunization against this virus. we aimed to design a novel peptide-based vaccine for RVFV using immunoinformatic approach to predict highly conserved epitopes against glycoprotein receptor" Gn and Gc" of M protein, that can mediate immune response which can use later to produce a new vaccine that could replace the conventional vaccine. A total of 118 sequences of M protein of RVFV were retrieved from NCBI database and stored as FASTA format for immunoinformatics analysis. ClustalW multiple alignment using BioEdit sequence alignment editor (v7.0.9) was performed to the retrieved sequences to identify the conserved region compared to M protein RVFV reference sequence under gene bank accession number [YP_003848705.1]. The B and T cell epitopes prediction is done by immune epitope database (IEDB). (IEDB) predicted B cell epitopes by Bepipred linear epitope prediction analysis and T cell epitopes using Major Histocompatibility Complex class I and ll binding prediction tool based on Stabilized Matrix Method (SMM). Allergenicity for the Helper T cell epitopes (HTL) predicted using AllerTop software. TAP transporter and Proteasomal cleavage for Cytotoxic T cell (CTL) were predicted from (IEDB). The population coverage over the world was determined. The four best predicted CTL namely (836HTYLQSVRK844, 672IPRYSTYLM680, 1085ILHFTVPEV1093 and 834FVHTYLQSV842) were docked with HLA-B*35 and suggested to be universal peptide vaccine for immunization against RVFV. The typical overlapping between the MHC Class I epitope (834FVHTYLQSV842) and MHC Class II (834FVHTYLQSV842) suggest the possibility to presenting these antigens to immune system via both MHC class I and II pathways. In conclusion; the four CTL epitopes are selected as vaccine candidates to develop safer and easier to manufacture without need of culture vaccine for prophylactic method against this virus. We recommend to confirm our result by doing additional in vivo and in vitro complementary steps to support this novel predicted vaccine.

rift valley fever virus immunoinformatic peptide vaccine & M protein

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Kasye, M., Teshome, D., Eshetu, A.A., 2016. A Review on Rift Valley Fever on Animal, Human Health and its Impact on Live Stock Marketing. Austin Virol and Retrovirology 3. Retrieved from
[2]  Sow, A., Faye, O., Ba, Y., Diallo, D., Fall, G., Faye, O., Sall, A. A., 2016. Widespread Rift Valley Fever Emergence in Senegal in 2013-2014. Open Forum Infectious Diseases, 3(3).
[3]  Nanyingi, M. O., Munyua, P., Kiama, S. G., Muchemi, G. M., Thumbi, S. M., Bitek, A. O., Njenga, M. K., 2015. A systematic review of Rift Valley Fever epidemiology 1931-2014. Infection Ecology & Epidemiology, 5(1), 28024.
[4]  Mottram, T. J., Li, P., Dietrich, I., Shi, X., Brennan, B., Varjak, M., & Kohl, A., 2017. Mutational analysis of Rift Valley fever phlebovirus nucleocapsid protein indicates novel conserved, functional amino acids. PLoS Neglected Tropical Diseases, 11(12).
[5]  Warimwe, G. M., Gesharisha, J., Carr, B. V., Otieno, S., Otingah, K., Wright, D., Hill, A. V. S., 2016. Chimpanzee adenovirus vaccine provides multispecies protection against rift valley fever. Scientific Reports, 6.
[6]  Gutiérrez AH, Spero D, Gay C, Zimic M, De Groot AS., 2012. New vaccines needed for pathogens infecting animals and humans: one health. Human vaccines & immunotherapeutics. 8(7): 971-8.
[7]  RVF virus facts sheet on National Center for Emerging and Zoonotic Infection Diseases CDC - Division of high consequences pathogens and pathology -2016, available at
[8]  Soi RK, Rurangirwa FR, McGuire TC, Rwambo PM, DeMartini JC, Crawford TB., 2010 Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine. Clinical and Vaccine Immunology. 17(12): 1842-9.
[9]  M.M., B., D., M., J., V., 2014. Cyclical outbreaks of rift valley fever in East Africa: Why they persist and possible solutions to prevent or contain its spread. American Journal of Tropical Medicine and Hygiene. Retrieved from
[10]  Faburay, B., LaBeaud, A. D., McVey, D. S., Wilson, W. C., & Richt, J. A., 2017. Current status of rift valley fever vaccine development. Vaccines. MDPI AG.
[11]  Hall, T., Biosciences, I., & Carlsbad, C., 2011. BioEdit: An important software for molecular biology. GERF Bulletin of Biosciences, 2(June), 60-61.
[12]  Fleri, W., Paul, S., Dhanda, S. K., Mahajan, S., Xu, X. Peters, B., & Sette, A., 2017. The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design. Frontiers in Immunology. Frontiers Research Foundation.
[13]  Larsen JE, Lund O, Nielsen M., 2006. Improved method for predicting linear B-cell epitopes. Immunome Res. 2(1): 2.
[14]  Lundegaard C, Lund O, Nielsen M., 2008. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics. 24(11): 1397-8.
[15]  Peters B, Sette A., 2005. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC bioinformatics. 6(1): 132.
[16]  Morshed MM, Gazi MA, Musa MA, Kibria MG, Uddin MJ, Khan MA, Hasan S., 2014. Computer aided prediction and identification of potential epitopes in the receptor binding domain (RBD) of spike (S) glycoprotein of MERS-CoV. Bioinformation. 10(8): 533-38.
[17]  Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A., 2008. Systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 4(4):e1000048. [PMID:18389056].
[18]  Nielsen M, Lundegaard C, Lund O., 2007. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC bioinformatics. 8(1): 238.
[19]  Khan MA, Hossain MU, Rakib-Uz-Zaman SM, Morshed MN., 2015. Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study. Scandinavian journal of immunology. 2015; 82(1):25-34.
[20]  Dimitrov I, Bangov I, Flower DR, Doytchinova I., 2014. AllerTOP v. 2-a server for in silico prediction of allergens. Mol Model. 20(6):2278.
[21]  Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE., 2004. UCSF Chimera-a visualization system for exploratory research and analysis. Journal of computational chemistry. 25(13):1605-12. [PMID: 15264254].
[22]  Källberg M, Wang H, Wang S, Peng J, Wang Z, Lu H, Xu J., 2012. Template-based protein structure modeling using the RaptorX web server. Nature protocols. 7(8): 1511-22.
[23]  Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, Denholm JT, Richards MJ, Rimmelzwaan GF, Kelso A, Doherty PC, Turner SJ., 2010. Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proceedings of the National Academy of Sciences. 107(28):12599-604.
[24]  Weiskopf D, Angelo MA, De Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et. al., 2013. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ Tcells. Proceedings of the National Academy of Sciences. 110(22):E2046-53. [PMID:23580623].
[25]  Singh S, Singh H, Tuknait A, Chaudhary K, Singh B, Kumaran S, Raghava GP., 2015. PEPstrMOD: structure prediction of peptides containing natural, non-natural and modified residues. Biology direct. 10(1):73.
[26]  Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE., 2000. The protein data bank. Nucleic Acids Res. 28(1):235-42.
[27]  Labbé CM, Rey J, Lagorce D, Vavruša M, Becot J, Sperandio O, Villoutreix BO, Tufféry P, Miteva MA., 2015. MTiOpenScreen: a web server for structure-based virtual screening. Nucleic Acids Res. 43(W1):W448-54.
[28]  Mashiach E, Schneidman-Duhovny D, Peri A, Shavit Y, Nussinov R, Wolfson HJ., 2010. An integrated suite of fast docking algorithms. Proteins: Structure, Function, and Bioinformatics. 78(15):3197-204.
[29]  Suvannang N, Nantasenamat C, Isarankura-Na-Ayudhya C, Prachayasittikul V., 2011. Molecular docking of aromatase inhibitors. Molecules. 16(5):3597-617.
[30]  Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A., 2006. Predicting population coverage of Tcell epitope-based diagnostics and vaccines. BMC bioinformatics. 7(1): 153. [PMID]:16545123.
[31]  World Health Organization. Guide line for production and quality control of synthetic peptide vaccine. WHO technical report series. 1999, No.989.
[32]  Singh, S. P., & Mishra, B. N., 2016. Major histocompatibility complex linked databases and prediction tools for designing vaccines. Human Immunology, 77(3), 295-306.
[33]  Paul S, Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A., 2013. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J Immunol. 191(12): 5831-9.
[34]  Peters B, Bulik S, Tampe R, Van Endert PM, Holzhütter HG. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol. 2003; 171(4): 1741-9.
[35]  Marshall NB, Swain SL., 2011. Cytotoxic CD4 T cells in antiviral immunity. BioMed Research International.
[36]  Osman MM, ElAmin EE, Al-Nour MY, Alam SS, Adam RS, Ahmed AA,, 2016. In Silico Design of Epitope Based Peptide Vaccine against Virulent Strains of (HN)-Newcastle Disease Virus (NDV) in Poultry Species. Int. J. of Multidisciplinary and Current research. 4, Available at:
[37]  Mohamed SS, Osman MM, Sami SM, Elgailany HA, Bushara MK, Hassan HA, et al., 2016. Immunoinformatics Approach for Designing Epitope-Based Peptides Vaccine of L1 Major Capsid Protein against HPV Type 16. Int. J. of Multidisciplinary and Current research. 4, Available at: